The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Bicycle has a wobble
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Triple meeting 2024 – Aktis radiotherapy heads for the clinic
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
ASCO-GU – Corbus throws its hat into the Nectin-4 ring
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
